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Summary
The survival rate of elderly hemodialyzed (HD) patients is commonly thought to be poor. In 
a prospective, single center, non-interventional, observational study, the cause of all-cause 
and cardiovascular (CV) and heart failure (HF) mortality in this patient group were examined 
and compared with a younger cohort (below 60 years). 
The study included 223 patients (90 women and 133 men) with age ranging from 34.5 to 75.0 
years treated with HD. Median duration of HD was 70.0 months (24.0-120.0). Mortality data 
was collected over a period of six years. We divided patients into groups: <60 (n=123), ≥60 years 
(n=100), and with (n=33) and without DM type 2 (n=190). 
During a six-year follow-up, 100 patients (44.8%) died, including 83 (37.2%) patients who died 
due to CV reasons. Median follow-up was 2015.0 days (946.0-2463.0) with the median time 
to death of 1166.0 days (654.5-1631.0). The factors negatively affecting patients’ survival in 
univariate Cox regression analysis included for all-cause mortality were: inter-dialytic weight 
gain (IDWG) (hazard ratio [HR]=1.60; p=0.01), ultrafiltration (UF) rate (HR=3.63; p=0.012) for 
group <60 years; for CV death: UF rate (HR=4.20; p=0.03), DM (HR=5.11; p=0.002) for group <60 
years; for HF death: mellitus type 2 (DM) (HR=2.93; p=0.027) for group ≥60 years). In a multi-
variate Cox regression analysis for patients <60 years, the UF rate was the only independent 
predictor of all-cause mortality (HR 3.63 (1.34-9.67); p=0.011). Both DM (HR 4.91 (1.71-14.10); 
p=0.003) and UF rate (HR 3.62 (1.04-12.61); p=0.044) were independent predictors of CV-related 
mortality in patients <60 years.
The UF rate can be a simple, useful indicator of higher long-term all-cause and CV mortality in 
HD patients <60 years of age. Also, DM may be a predictor of CV–related mortality in younger 
HD patients. 
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IntroductIon
In hemodialyzed (HD) patients, high interdialytic weight 
gain (IDWG), a high ultrafiltration rate (UFR), and short 
session duration have been associated with poor outco-
mes [16]. The major causes of death are cardiovascular 
(CV) and infectious [17,27]. CV complications are related 
to coronary artery disease, congestive heart failure (HF), 
arrhythmias and sudden cardiac death (SCD) [3,11]. In 
the study by Go et al. [11], the risk of adverse CV events 
was 43% higher in patients with an estimated glome-
rular filtration rate (eGFR) between 45 and 59 ml/min 
and 343% higher in those with end stage renal disease 
(ESRD) as compared to the control group with a normal 
GFR. The presence of either baseline or progressive left 
ventricular hypertrophy (LVH) is strongly associated 
with adverse outcomes.
To prevent volume overload (hypertension, LVH) and to 
maintain the fluid balance, even 5-6 liters of fluid have to 
be removed during each HD session. Rapid fluid remo-
val or ultrafiltration (UF) during a short period of time 
can lead to intradialytic hypotension (IDH) in 25-50% of 
patients [10]. Moreover, IDH has been associated with 
myocardial stunning, cerebral atrophy as well as an incre-
ased risk for coronary and cerebral ischemic events, and 
vascular access thrombosis. Also, it is a major cause of 
morbidity in elderly HD patients and those with CV com-
plications [10,20]. The impact of HD parameters on out-
comes in younger patients is less established.
HD patients with diabetes mellitus (DM) have higher 
rates of several comorbidities and experience poorer 
clinical outcomes compared with patients without DM 
[18]. In a study conducted by Rhee et al. [24] higher 
HbA1C levels were significantly associated with higher 
rates of CV mortality and MI  in a large cohort of HD 
patients with DM. Increased mortality and morbidity are 
reported in association with high UFR, IDWG, with long 
dialysis recovery time and diabetes [16,18,22,33]. Howe-
ver, the association between parameters of HD session 
in patient group above and below 60 years and in DM 
patients and without DM has not been studied yet.
The aim of the our prospective, observational study was 
to assess the effect of HD parameters: IDWG, UF rate, dry 
weight, duration of the dialysis session, blood flow, HD 
vintage and age, DM on all-cause, CV- and HF- related 
mortality in HD patients <60 years of age during six-year 
follow-up. 
MaterIals and Methods
The study included 223 patients (90 female and 133 
male), age from 34.5 to 75.0 years, treated with long-
-term regular thrice-weekly HD for at least six months 
due to CKD. Patients with stroke, myocardial infarction 
(MI) or limb ischemia in the previous six months or who 
had chronic atrial fibrillation or morbid obesity (body 
mass index >40 kg/m2) were excluded. Then patients 
were prospectively followed for six years and the data 
on all-cause, CV- and HF-related mortality was collec-
ted. Patients who received a kidney transplant during 
the observation period were only followed up to suc-
cessful treatment. CV mortality was defined as death 
due to MI or stroke. HF-related mortality was defined 
as death related only to HF. The date and cause of death 
was determined based on patients’ hospital records. The 
researcher who collected the mortality data was blinded 
to the results of laboratory tests and clinical data.
clInIcal data
The following variables were collected at baseline: 
age, sex, CKD patients with diagnosis of type 2 DM and 
without DM, HD parameters: IDWG between HD session, 
UF rate, dry weight, duration of the dialysis session, 
blood flow and HD vintage. 
The UF rate is the rate of volume removal at dialysis, 
expressed in ml/h/kg body weight, measured by the 
weight change per duration of HD treatment using 
the post HD weight as a denominator. The value of UF 
rate used in the analysis was the mean UF rate for each 
patient over the first 12 months of the study.
Dry weight was clinically determined using the stan-
dard protocol and reflects the lowest weight the patient 
can tolerate without intradialytic symptoms and hypo-
tension in the absence of overt fluid overload and was 
modified by the attending doctor as needed.
Blood flows were the mean values for each patient over 
the first 12 months of the study.
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conducted separately for patients aged <60 years and 
≥60 years. Results of univariate and multivariate analy-
ses were presented as hazard ratios (HR) with 95% con-
fidence intervals [95%CI]. 
In addition, the risk of all-cause, CV and HF-related 
death in patients with vs. without DM was presented as 
odds ratios (OR) with 95%CI. The Breslow-Day test was 
used to compare the homogeneity of the ORs between 
age groups.
All tests were two tailed and a p value of <0.05 was con-
sidered to be statistically significant. 
All statistical analyses were performed using SPSS 15.0 
(SPSS Inc., Chicago, IL, USA).
results
Patients’ characteristics and HD parameters are presen-
ted in Table 1.
During a six-year follow-up, 100 patients (44.8%) died, 
including 83 (37.2%) patients who died due to CV causes 
in 64 (28.7%) patients and 19 (8.5%) patients who died 
due to HF (Table 2). The median follow-up was 2015.0 
days (946.0-2463.0) with the median time to death of 
1166.0 days (654.5-1631.0). The median time to kidney 
transplantation was 978.5 days (452.5-1735.0).
We divided patients into groups according to age: <60 
(n=123), >60 years (n=100), and according to DM pre-
sence: with (n=33) and without DM (n=190). The factors 
negatively affecting patients’ survival in univariate Cox 
regression included: for all-cause mortality: the IDWG 
(HR=1.60; p=0.01), UF rate (HR=3.63; p=0.012) for group 
<60 years (Table 3); for CV death: UF rate (HR=4.20; 
p=0.03), DM (HR=5.11; p=0.002) for group <60 years 
Absolute IDWG was abstracted from patients’ history 
documentation and was defined as predialysis weight 
from one treatment minus postdialysis weight from 
the prior treatment, which represents fluid accumu-
lation between dialysis treatments (1 kg weight gain 
equals approximately 1 liter fluid accumulated). The 
value of IDWG used in the analysis was the mean IDWG 
for each patient over the first 12 months of the study. 
Relative IDWG was calculated as a percentage of post-
dialysis weight. It described the amount of fluid accu-
mulated between dialysis treatments as a function of 
the patient’s body size. Median duration of HD was 70.0 
(24.0-120.0) months. 
The study was approved by the Bioethics Committee of 
the Jagiellonian University and all patients signed an 
informed consent for their participation.
statIstIcal Methods
Results were presented as numbers (percentages) of 
patients or medians (inter-quartile range) where appli-
cable. Differences between groups were tested using 
the chi-square test and Fisher’s exact test for dichoto-
mous variables and the Mann–Whitney U test or the 
Kruskal-Wallis test for continuous variables. Survival 
curves were computed using the Kaplan–Meier method. 
Associations between clinical/HD-related factors and 
all-cause, CV, HF-related death during follow-up were 
estimated using univariate Cox regression analysis. In 
addition, multivariate Cox proportional hazard regres-
sion analysis was performed to find independent pre-
dictors of all-cause, CV, and HF-related death. Forward 
selection with a probability value for covariates to enter 
the model was set at the 0.05 level. The following cova-
riates were tested: gender, presence of diabetes mellitus, 
HD-related factors (IDWG, relative IDWG, UF rate, dura-
tion of HD session, blood flow, HD vintage). Analysis was 
Table 1. Study group characteristics
Variable Maintained HD patients (n=91) Patients who died (n=100) P value*
Male 49 (53.8%) 61 (61.0%) 0.38
Age [years] 55.0 (47.5-63.5) 66.0 (55.5-75.0) <0.001
Age ≥60 years 29 (31.9%) 68 (68.0%) <0.001
DM 11 (12.1%) 20 (20.0%) 0.17
Dry weight [kg] 65.0 (54.5-74.5) 62.5 (55.3-72.8) 0.60
IDWG [kg] 3.4 (2.7-3.9) 3.3 (2.8-4.0) 0.55
Relative IDWG [%] 5.2 (4.2-6.1) 5.3 (4.4-6.4) 0.72
UF rate [mL/kg/h] 1.3 (1.0-1.5) 1.3 (1.1-1.6) 0.33
Duration of the dialysis session 
[minutes]
240.0 240.0 (210.0-240.0) 0.29
Blood flow [mL/min] 250.0 250.0 (250.0-250.0) 0.25
HD vintage [months] 70.0 (24.0-120.0) 43.5 (20.0-120.0) 0.14
HD- hemodialysis, DM- diabetes mellitus, KTx- kidney transplant, UF- ultrafiltration, IDWG- inter-dialytic weight gain; *Values are presented as numbers 
(percentages) or medians (inter-quartile range)
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(2.28-44.63), p=0.002), DM (HR 4.33 (1.72-10.87), p=0.002) 
and IDWG (HR 0.54 (0.31-0.93), p=0.026) were indepen-
dently associated with HF-related death.
Kaplan-Meier survival curves stratified by age group 
and DM status for all-cause, CV and HF-related morta-
lity are presented in Figures 1 and 2 respectively. The 
crude rates of all-cause, CV- and HF-related mortality 
stratified by age and DM status is shown in Figure 3. A 
significant interaction between age group and impact 
of DM on mortality was confirmed only for CV death. 
DM increases the risk of CV mortality only in the sub-
(Table 4); for HF death: DM (HR=2.93; p=0.027) for group 
≥60 years (Table 5). In multivariate Cox regression analy-
sis for patients <60 years, UF rate was the only indepen-
dent predictor of all-cause mortality (HR 3.63 (1.34-9.67); 
p=0.011). Both DM (HR 4.91 (1.71-14.10); p=0.003) and UF 
rate (HR 3.62 (1.04-12.61); p=0.044) were predictors of 
CV-related death in HD patients <60 years. 
However, in the overall population age ≥60 years was the 
only independent predictor of all-cause (HR 3.37 (2.21-
5.14); p<0.001) and CV mortality (HR 4.40 (2.52-7.67); 
p<0.001). On the other hand, age ≥60 years (HR 10.09 
Table 2. Mortality
All (n=223)
Age <60 
(n=123)
Age ≥60 
(n=100)
p value DM (-) (n=190) DM (+) (n=33) p value
All cause 100 (44.8%) 32 (26.0%) 68 (68.0%) <0.001* 80 (42.1%) 20 (60.6%) 0.049
CV 64 (28.7%) 17 (13.8%) 47 (47.0%) <0.001* 47 (24.7%) 17 (51.5%) 0.002
HF 19 (8.5%) 2 (1.6%) 17 (17.0%) <0.001* 9 (4.7%) 10 (30.3%) <0.001*
CV- cardiovascular, HF-heart failure, DM-diabetes mellitus; * differences statistically significant
Table 3. Univariate Cox regression analysis for all-cause death
Variable
All (n=223) Age <60 years (n=123) Age ≥60 years (n=100) DM (-) (n=190) DM (+) (n=33)
HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value
Male vs. 
female
1.17 (0.78-
1.75)
0.44
1.21 (0.60-
2.44)
0.59
0.92 (0.56-
1.51)
0.75
1.31 (0.83-
2.07)
0.25
0.77 (0.32-
1.86)
0.56
Age (per 1 
year)
1.06 (1.04-
1.07)
<0.001*
1.04 (1.00-
1.09)
0.08
1.07 (1.03-
1.10)
<0.001*
1.07 (1.05-
1.09)
<0.001*
1.02 (0.98-
1.05)
0.34
Age ≥60 vs. 
<60 years
3.17 (2.08-
4.83)
<0.001* - - - -
3.69 (2.32-
5.87)
<0.001*
1.22 (0.44-
3.36)
0.70
DM vs. no 
DM
1.40 (0.86-
2.29)
0.18
2.43 (0.93-
6.31)
0.07
0.78 (0.44-
1.38)
0.38 - - - -
Dry Weight 
[kg]
1.00 (0.98-
1.01)
0.53
0.99 (0.97-
1.03)
0.96
0.99 (0.97-
1.00)
0.12
0.99 (0.98-
1.01)
0.39
1.00 (0.96-
1.03)
0.79
IDWG [kg]
1.04 (0.85-
1.27)
0.73
1.60 (1.11-
2.31)
0.012*
0.88 (0.69-
1.13)
0.31
1.07 (0.85-
1.35)
0.57
0.92 (0.62-
1.38)
0.69
Relative 
IDWG [%]
1.00 (1.00-
1.00)
0.75
0.99 (0.99-
1.01)
0.74
1.01 (0.86-
1.19)
0.90
1.00 (0.99-
1.01)
0.74
0.99 (0.74-
1.32)
0.94
UF rate [mL/
kg/h]
1.50 (0.90-
2.52)
0.12
3.63 (1.34-
9.87)
0.011*
1.26 (0.69-
2.30)
0.46
1.55 (0.86-
2.78)
0.15
1.32 (0.45-
3.87)
0.62
Duration of 
the dialysis 
session 
[minutes]
1.00 (0.99-
1.00)
0.21
1.01 (0.99-
1.02)
0.36
0.99 (0.99-
1.00)
0.10
1.00 (0.99-
1.01)
0.55
0.99 (0.98-
1.01)
0.35
Blood flow 
[mL/min] 
0.99 (0.98-
1.00)
0.28
1.00 (0.99-
1.02)
0.61
0.98 (0.97-
1.00)
0.040*
1.00 (0.99-
1.01)
0.50
0.98 (0.95-
1.02)
0.34
HD period 
[month] 
1.00 (1.00-
1.00)
0.28
1.00 (0.99-
1.00)
0.22
1.00 (1.00-
1.00)
0.72
1.00 (1.00-
1.00)
0.73
0.99 (0.97-
1.01)
0.17
HD- hemodialysis, DM- diabetes mellitus, UF- ultrafiltration, IDWG- inter-dialytic weight gain; *p<0.05; data presented as hazard ratio (HR) with 95% confidence 
interval (95%CI)
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Table 4. Univaria te Cox regression analysis for CV death
All (n=223) Age <60 years (n=123) Age ≥60 years (n=100) DM (-) (n=190) DM (+) (n=33)
HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value
Male vs. 
female 
0.96 (0.58-
1.57)
0.86
1.03 (0.40-
2.66)
0.96
0.73 (0.41-
1.30)
0.28
1.08 (0.61-
1.94)
0.79
0.69 (0.27-
1.80)
0.45
Age, years
1.07 (1.05-
1.09)
<0.001*
1.04 (0.98-
1.11)
0.18
1.09 (1.05-
1.14)
<0.001*
1.09 (1.06-
1.12)
<0.001*
1.01 (0.98-
1.05)
0.43
Age ≥60 
years
4.07 (2.34-
7.10)
<0.001* - - - -
5.40 (2.80-
10.41)
<0.001*
0.98 (0.35-
2.79)
0.97
DM vs. no 
DM
2.01 (1.15-
3.50)
0.014*
5.11 (1.80-
14.54)
0.002*
0.93 (0.48-
1.80)
0.83 - - - -
Dry weight 
[%]
0.99 (0.97-
1.01)
0.38
1.00 (0.96-
1.04)
0.96
0.98 (0.96-
1.00)
0.08
0.99 (0.97-
1.01)
0.27
0.99 (0.96-
1.03)
0.57
IDWG [kg]
0.99 (0.77-
1.28)
0.95
1.57 (0.95-
2.59)
0.08
0.87 (0.65-
1.17)
0.35
0.96 (0.71-
1.30)
0.80
1.04 (0.69-
1.56)
0.86
Relative 
IDWG [%]
1.00 (0.98-
1.01)
0.81
1.00 (0.99-
1.01)
0.82
1.04 (0.86-
1.25)
0.69
1.00 (0.98-
1.02)
0.84
1.11 (0.82-
1.50)
0.49
UF rate [mL/
kg/h]
1.71 (0.91-
3.23)
0.10
4.20 (1.09-
16.19)
0.037*
1.54 (0.77-
3.07)
0.22
1.60 (0.75-
3.39)
0.23
1.91 (0.60-
6.03)
0.27
Duration of 
the dialysis 
session 
[minutes]
0.99 (0.98-
1.00)
0.024*
1.00 (0.98-
1.02)
0.82
0.99 (0.98-
0.99)
0.035*
0.99 (0.98-
1.00)
0.07
1.00 (0.98-
1.01)
0.58
Blood flow 
[mL/min]
0.99 (0.98-
1.01)
0.26
1.00 (0.97-
1.02)
0.77
0.99 (0.97-
1.00)
0.12
1.00 (0.98-
1.01)
0.50
0.99 (0.95-
1.02)
0.44
HD period 
[months]
1.00 (1.00-
1.00)
0.42
1.00 (0.99-
1.01)
0.44
1.00 (1.00-
1.01)
0.77
1.00 (1.00-
1.01)
0.76
0.99 (0.97-
1.01)
0.21
HD- hemodialysis, DM- diabetes mellitus, UF- ultrafiltration, IDWG- inter-dialytic weight gain; *p<0.05; data presented as hazard ratio (HR) with 
95% confidence interval (95% CI)
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More importantly, most of these parameters are modi-
fiable factors and thus these results may identify possi-
ble room for improvement of the prognosis of patients 
with CKD. 
According to earlier reports, CV disorders lead to death 
in about 46-60% of patients with renal failure treated 
with HD [31]. CV diseases are the most frequent cause 
of death in incident (37.9%) and prevalent HD (42.3%) 
patients. The strongest influence of mortality is exerted 
by acute MI, congestive heart failure (CHF), arrhythmia, 
cardiac arrest and cerebrovascular accidents [15]. Accor-
ding to the European Renal Registry [5], patients aged 
65-74 years, which is the commonest age group star-
ting dialysis, can expect to live about five years, 50% less 
than those in the same age group in the general popu-
lation. For younger dialysis patients, <45 years of age, 
CV mortality is even higher, exceeding 100 times [15]. 
The primary cause of CV death in  ESRD patients is SCD. 
According to Dialysis Outcomes and Practice Patterns 
(DOPPS) SCD constitute 33% of HD deaths in the United 
group of younger patients. HF-related death was higher 
in patients with than without DM only in patients ≥60 
years of age. However, the lack of a significant interac-
tion between age group and impact of DM on HF-death 
may suggest some harmful effect of DM also in younger 
patients. 
dIscussIon
In our prospective, observational study 223 HD patients 
were followed up for six years. We considered factors 
particularly associated with HD parameters, which may 
affect mortality in patients <60 years of age. We sho-
wed that in HD patients <60 years, the factors negatively 
affecting mortality are IDWG and UF rate (for all-cause 
mortality) and UF rate and DM (for CV death). To our 
knowledge, the association between parameters of HD 
session in the patient group above and below 60 years 
and in DM patients and without DM has not been stu-
died yet.
Table 5. Univariate Cox regression analysis for HF death
All (n=223) Age <60 years (n=123) Age ≥60 years (n=100) DM (-) (n=190) DM (+) (n=33)
HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value HR (95%CI) p value
Male vs. 
female
0.86 (0.28-
1.67)
0.40
0.96 (0.06-
15.44)
0.98
0.48 (0.18-
1.23)
0.13
0.59 (0.16-
2.21)
0.44
0.77 (0.22-
2.66)
0.68
Age, years
1.15 (1.09-
1.21)
<0.001*
1.08 (0.86-
1.35)
0.50
1.17 (1.09-
1.26)
<0.001*
1.20 (1.11-
1.30)
<0.001*
1.05 (0.99-
1.12)
0.11
Age ≥60 years
12.81 (2.96-
55.48)
0.001* - - - -
15.23 (1.90-
122.00)
0.010*
3.63 (0.46-
28.66)
0.22
DM vs. no DM
6.05 (2.46-
14.90)
<0.001*
12.20 (0.76-
196.89)
0.08
2.93 (1.13-
7.59)
0.027* - - - -
Dry weight 
[kg]
0.97 (0.93-
1.00)
0.08
0.83 (0.66-
1.04)
0.11
0.97 (0.93-
1.00)
0.08
0.94 (0.88-
1.00)
0.046*
0.97 (0.92-
1.02)
0.21
IDWG [kg]
0.58 (0.36-
0.94)
0.027*
0.34 (0.08-
1.50)
0.16
0.64 (0.38-
1.07)
0.09
0.40 (0.19-
0.82)
0.013*
0.81 (0.45-
1.47)
0.49
Relative IDWG 
[%]
0.85 (0.63-
1.14)
027
0.89 (0.37-
2.14)
0.79
0.93 (0.66-
1.29)
0.65
0.77 (0.50-
1.19)
0.24
1.03 (0.69-
1.53)
0.89
UF rate [mL/
kg/h]
1.25 (0.38-
4.10)
0.72
5.80 (0.11-
299.45)
0.38
1.34 (0.41-
4.39)
0.63
0.71 (0.12-
4.35)
0.71
1.82 (0.40-
8.25)
0.44
Duration of the 
dialysis session 
[minutes]
0.98 (0.96-
0.99)
0.002*
0.96 (0.92-
1.01)
0.13
0.98 (0.97-
1.00)
0.015*
0.97 (0.95-
0.99)
0.014*
0.99 (0.97-
1.01)
0.42
Blood flow 
[mL/min]
0.98 (0.96-
1.01)
0.18
0.98 (0.92-
1.05)
0.56
0.97 (0.93-
1.01)
0.15
0.98 (0.95-
1.02)
0.28
0.99 (0.95-
1.04)
0.70
HD period 
[months]
0.98 (0.97-
1.00)
0.012*
0.97 (0.91-
1.03)
0.29
0.99 (0.97-
1.00)
0.05
0.98 (0.97-
1.00)
0.07
1.00 (0.97-
1.02)
0.61
HD- hemodialysis, DM- diabetes mellitus, UF- ultrafiltration, IDWG- inter-dialytic weight gain, *p<0.05; data presented as hazard ratio (HR) with 
95% confidence interval (95%CI)
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diate period following dialysis initiation is a very high 
CV risk period, characterized by a much higher rate of 
major CV events than the remainder of the first two 
years. Incidence rates that were at least three- and up 
to eight-fold higher than during the second year on dia-
lysis were found for CV events. The first-year CV event 
rate (30.2/100) greatly exceeded the second-year rate 
(19.4/100). About one-third of all strokes in dialysis 
patients were found to occur during or shortly after HD 
treatment.
States, 23% in Japan, 19% in Australia/New Zealand and 
18% in Canada [23]. The lack of SCD in our study is pro-
bably related to the incorrect eligibility of SCD in the 
diagnosis of acute MI. In our study, the median time to 
death was three years.
In fact, the HD procedure itself has been recognized 
to induce myocardial stunning and contractile dys-
function, endothelial dysfunction and oxidative stress. 
Eckard et al. [7], thought that initiation of dialysis trig-
gers CV event. The author has shown that the imme-
Fig. 1. Kaplan-Meier survival curves by age groups (age <60 years, solid line; 
age ≥60 years, dotted line) for all-cause death (A), cardiovascular death (B) 
and heart failure-related death (C)
Fig. 2. Kaplan-Meier survival curves by diabetes status (no diabetes mellitus, 
solid line; diabetes mellitus, dotted line) for all-cause death (A), cardiovascular 
death (B) and heart failure-related death (C)
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follow-up had increased risks of CHF, MI, and stroke, as 
compared with patients whose serum creatinine did not 
double. Age, diabetes and dialytic age have a strong rela-
tionship with the occurrence of CV disease in patients 
treated with HD [15]. Among HD patients, the observed 
risk of death from DM is higher as compared to the gen-
eral population [29]. In patients with DM treated with 
HD over a twenty-year period a lower survival rate was 
observed in comparison to patients with glomerulone-
phritis and adult polycystic kidney disease [28]. Data 
from the Australia and New Zealand Dialysis and Trans-
plant Registry (ANZDATA) showed that in type 1 DM, HR 
of death was 1.64 and in type 2 DM it was 1.13 as com-
pared to patients with ESRD but without DM [25,32]. We 
revealed that DM significantly increases the risk of CV 
death in patients <60 years of age and HF-related mor-
tality in the subgroup of older patients. Our research 
presented that DM was an independent predictor of 
CV-related death in young HD people. Probably, both CV 
calcification, arterial stiffness and autonomic dysfunc-
tion frequently observed in diabetic young HD patients 
could increase all-cause and CV mortality in this group 
[25]. Also, high UF rates affect intradialytic hypotension 
and could be associated with increased mortality [33] 
According to earlier reports [21], patients with poor glu-
cose control showed worse survival than patients with 
HbA1c <8%. A subgroup analysis for patients stratified 
by age revealed that HbA1c ≥8% was a predictor of mor-
tality in patients from the age <55 and age 55–64 gro-
ups but not in the age ≥65 group. In this study, dialysis 
and age, poor glucose control negatively affected survi-
val only in the age <55 years group among HD patients. 
Subgroup analysis dividing cases by age revealed that 
glycemic control was not associated with mortality in 
patients >65 years old. Similarly, Adler et al. [1] investi-
gated DM patients on HD, and found that HbA1c levels 
exceeding 8.5% were associated with poorer survival 
only in patients <60 years of age.
Also, Cea Soriano et al. [3] in a huge cohort of 57,946 
patients with type 2 DM showed high overall incidence 
rates of death (mean follow-up time of 6.76 years), MI 
(6.64 years) and stroke (6.56 years) - 43.65, 9.26 and 10.39 
cases per 1000 person-years, respectively. A CKD stage 4 
was associated with an increased risk of death, MI and 
stroke. Other predictors of death, MI and stroke included 
age, longer duration of DM, poor control of diabetes, 
hyperlipidemia, smoking and history of CV events. High 
UF rates can result in intradialytic hypotension and are 
associated with increased mortality [22]. 
Reduced kidney function has been proposed as a risk 
factor for the deterioration of prevalent HF as well as a 
risk factor for incident HF [31]. CV events are not only 
restricted to ESRD; early CKD stages are also associated 
with variable degrees of HF as underlined in the Ath-
erosclerosis Risk in Communities (ARIC) population 
study [14]. Statistical analysis found an increase in HF in 
subjects with an eGFR <60 ml/min/1.73 m2. Cox regres-
DM is the main cause of initiation renal replacement 
therapy in the world, and is considered as an indepen-
dent risk factor for mortality in patients with ESRD. 
That was confirmed by studies from Schneider et al. 
[26], who identified more than 27,000 CKD patients with 
diagnosis of type 2 DM. During nine-year follow-up, 
693 patients developed angina pectoris, 1069 CHF, 508 
MI, 970 stroke, and 578 transient ischemic attacks. Dia-
betic patients whose serum creatinine doubled during 
Fig. 3. All-cause (A), cardiovascular (B) and heart failure-related mortality 
(C) stratified by age and diabetes status
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and vascular and valvular calcification [12,30]. On the 
other hand, CV diseases increase the number of episo-
des of hypotension. A study of Kalanter-Zadeh et al. [13] 
demonstrated that IDH is related to IDWG, which has 
been associated with a higher risk of all-cause and CV 
mortality over the range from 1.0-1.49 to >4.0 kg of fluid 
weight gain. In another study [2] relative IDWG >3.5 % 
body weight was independently associated with MI, CV 
mortality and were consistent among patients with and 
without DM, and with and without baseline HF. Absolute 
IDWG >3 kg was associated with outcomes other than 
MI. On an unadjusted basis, higher absolute IDWG was 
associated with a greater risk of hospitalization for HF/
volume overload. Similarly, significant adjusted associa-
tions were observed for all-cause mortality (7 % greater 
risk), and HF/volume overload (14 % greater risk). 
Summarizing, better glycemic control in DM patients, 
smaller IDWG and UF rate can improve prognosis in 
young, CKD patients treated with HD.
lIMItatIons of the study
The main limitation of our study is the limited num-
ber of patients included. Therefore, a multicenter trial 
may result in a better revaluation of this aspect of HD 
patients.
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conclusIons 
UF rate can be a simple, useful indicator of higher long-
-term all-cause and CV mortality in HD patients <60 
years of age. Also, DM may be predictor of CV–related 
death in younger HD patients. 
sion analysis demonstrated a relative hazard of inci-
dent HF of 1.10 in subjects with a GFR range of 60-89 
ml/min/1.73 m2 and of 1.94 in those with a GFR <60 ml/
min/1.73 m2 [14,31]. CV events and mortality in CKD 
patients may be related to severity and persistence of 
LVH, which is typical feature of CKD- related cardiomi-
opathy. Eccentric or asymmetric LV development up to 
LV fibrosis can result from activation of the renin-angio-
tensin system, inhibition of nitric oxide synthesis, intra-
vascular volume expansion, secondary anemia, and the 
presence of arteriovenous fistulas [6,31].
It is worth noting that our patients had no history of 
CV events in the previous six months before the start 
of the study. Foley et al. [9] demonstrated that even HD 
patients without previous cardiac diseases can develop 
LVH associated to the time on dialysis. An increased LV 
mass volume index was observed in 62% of patients after 
18 months of incident HD and 49% of them developed 
overt LV failure. However, Charytan et al. [4] reported 
that 79-85% of patients beginning dialysis had LVH at 
the time of inauguration. 
In our study, the death of HF has been closely related to 
age, IDWG and duration of the dialysis session. During 
a six-year observation period, 19 (8.5%) patients died 
due to HF, including only 2 patients <60 years and 17 >60 
years. 
Both volume overload and aggressive fluid removal can 
induce circulatory stress and multi-organ injury. Cabrera 
et al. [2] demonstrated that IDWG was associated with 
higher CV morbidity and mortality. Also, in our study 
IDWG plays an important role. IDWG and higher net 
UF during dialysis were associated with all-cause mor-
tality during the observation period in patients under 
60 years. A high UF rate during HD is associated with a 
biochemical evidence of myocardial injury. Flyth et al. 
[8] showed that higher UF rate (approximately 3.5 liter 
removed over four-hour HD) was associated with incre-
ased risk of CV mortality (HR = 1.71) over against lower 
UF rate (approximately 2.8 liter removed over four-hour 
HD) with HR = 1.59. In our study higher UF rate was the 
independent associated with increased all-cause and 
CV mortality in younger patients, <60 years of age. Also 
Mavrakanas et al. [19] showed that high UF, high IDWG, 
and the duration of the dialysis session, were associa-
ted with troponin I elevation and was associated with 
a higher risk of mortality and major adverse CV events. 
While high UF rate is closely associated with interdialy-
tic hypotension (IDH), which is a frequent complication 
of HD and, it is associated with increased CV events. Epi-
sodes of IDH result from: a reduction of circulating blood 
volume due to ultrafiltration, rapid decrease in extra-
cellular osmolality associated with urea and sodium 
removal and coexisting imbalance between ultrafiltra-
tion and fluid refling. Episodes of IDH can be correlated 
with the presence of CV diseases for example: athero-
sclerosis, ischemic heart disease, LVH, cardiomyopa-
thy, congestive HF, numerous ventricular arrhythmias 
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